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Abstract
Context: Adipokines are linked to the development of cardiovascular dysfunction in type 2 diabetes (DM2). In DM2-patients,
circulating levels of omentin-1, an adipokine preferentially expressed in epicardial adipose tissue, are decreased. This study
investigated whether omentin-1 has a cardioprotective function.
Methods: Omentin-1 levels in plasma and cardiac fat depots were determined in DM2-patients versus controls. Moreover,
the relation between omentin-1 levels and cardiac function was examined in men with uncomplicated DM2. Finally, we
determined whether omentin-1 could reverse the induction of cardiomyocyte dysfunction by conditioned media derived
from epicardial adipose tissue from patients with DM2.
Results: Omentin-1 was highly expressed and secreted by epicardial adipose tissue, and reduced in DM2. Circulating
omentin-1 levels were lower in DM2 versus controls, and positively correlated with the diastolic parameters early peak filling
rate, early deceleration peak and early deceleration mean (all P,0.05). The improved diastolic function following
pioglitazone treatment associated with increases in omentin-1 levels (P,0.05). In vitro, exposure of cardiomyocytes to
conditioned media derived from epicardial adipose tissue from patients with DM2 induced contractile dysfunction and
insulin resistance, which was prevented by the addition of recombinant omentin.
Conclusion: These data identify omentin-1 as a cardioprotective adipokine, and indicate that decreases in omentin-1 levels
could contribute to the induction of cardiovascular dysfunction in DM2.
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Introduction
Cardiac dysfunction and myocardial insulin resistance are
common in patients with type 2 diabetes (DM2) [1,2]. Recent
studies have implicated adipokines in the pathogenesis of these
cardiac alterations [3–6]. Omentin-1 is an adipokine with
decreased circulating levels in conditions associated with insulin
resistance [7–12]. Plasma omentin-1 levels inversely correlate with
body mass index (BMI), fat mass, and fasting plasma insulin, and
positively with insulin sensitivity, adiponectin, high density
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lipoprotein cholesterol, and endothelial function [8,10,11,13,14].
In vitro, omentin-1 enhances insulin-mediated stimulation of Akt-
phosphorylation, glucose uptake and inhibits tumor necrosis factor
a-induced inflammation [15,16]. This indicates that omentin-1,
like adiponectin, may act as a protective adipokine.
Omentin-1 is abundantly expressed in epicardial adipose tissue
(EAT), a visceral fat depot located around the heart and coronary
arteries [5,17]. Since EAT is not separated by a fascia from the
myocardium, factors secreted from EAT may directly affect
cardiac function [3,5,18,19]. We examined whether omentin-1
expression and secretion in various adipose tissue depots, including
EAT, pericardial, and subcutaneous adipose tissue, is altered in
patients with DM2. Furthermore, we evaluated whether omentin-
1 levels were associated with metabolic and cardiac parameters in
men with uncomplicated DM2 before and after intervention with
the insulin-sensitizing drug pioglitazone, which is known to act
predominantly on adipose tissue and was shown to improve
cardiac diastolic function in this cohort [20,21]. Finally, we
examined whether recombinant omentin-1 prevents the abroga-
tion of insulin action and induction of contractile dysfunction in
primary rat cardiomyocytes by conditioned media derived from
EAT from patients with DM2.
Materials and Methods
Patient Characteristics
The patient samples used in this study were collected from two
distinct cohorts.
At the University Hospital in Duesseldorf (Germany), Caucasian
men undergoing coronary artery bypass grafting with or without
additional valve replacement surgery consented to the collection of
biopsies from EAT, pericardial, and intrathoracic subcutaneous
adipose tissue after written informed consent. The procedure to
obtain adipose tissue samples was approved by the medical ethical
committee of the Heinrich-Heine-University (Duesseldorf, Ger-
many), and the study was conducted in accordance with the
principles of the Declaration of Helsinki. Patients of other ethnic
origins, diagnosed as having human immunodeficiency virus
infection, lipodystrophy or chronic coexistent inflammatory
disease were excluded from participation. Participants were
distributed into two groups, i.e. those with and those without
DM2, on the basis of the diagnosis ‘DM2’ in the medical record of
the patient. Adipose tissue biopsies were either used to generate
conditioned media (CM), or snap-frozen in liquid nitrogen and
stored at 280uC for protein extraction.
Circulating omentin-1 levels were determined in 78 men with
uncomplicated DM2 from the previously described PIRAMID
(Pioglitazone Influence on tRiglyceride Accumulation in the
Myocardium in Diabetes) study [22] and 14 healthy men, aged
45–65 years, with normal glucose metabolism as determined by
a 75-g oral glucose tolerance test, which served as control subjects
[23] (Clinical trial registration number (unique identifier):
ISRCTN53177482; URL: http://www.controlled-trials.com/
ISRCTN53177482). Participating healthy controls and men with
uncomplicated DM2 had a body mass index (BMI) between 25–
32 kg/m2, and a blood pressure lower than 150/85 mm Hg (with
or without the use of antihypertensive drugs). Furthermore, only
DM2 patients with glycosylated hemoglobin (HbA1c) between
6.5–8.5% were eligible for inclusion. Patients with DM2 diagnosed
as having any symptoms or history of diabetes-related complica-
tions, or cardiovascular or liver disease, as well as prior use of
thiazolidinediones or insulin, were excluded from participation.
Exclusion criteria for healthy controls were a history or current
cardiovascular disease, dyslipidemia, and the use of any prescribed
medication. The clinical studies were conducted at two university
medical hospitals in the Netherlands (Leiden University Medical
Center, Leiden, and VU University Medical Center, Amsterdam),
were approved by the medical ethics committee of both centers,
and performed in full compliance with the Declaration of Helsinki.
Eligible participants with DM2 ceased their regular blood glucose
lowering agents before entering a 10-week run-in period in which
they were transferred to glimepiride monotherapy and titrated
until a stable dose was reached 2 weeks before randomization.
Then, participants with DM2 were randomized to pioglitazone
(15 mg once daily, titrated to 30 mg once daily after 2 weeks) or
metformin (500 mg twice daily, titrated to 1000 mg twice daily) in
addition to glimepiride throughout the study. Details on
assessment of cardiac function, aortic pulse wave velocity and
distensibility, and volume of pericardial and visceral abdominal
adipose tissue in the study groups have been described elsewhere
[21–24]. Insulin sensitivity was assessed by a euglycemic hyper-
insulinemic clamp using an insulin infusion rate of 40 mU.m22.-
min21 as previously described [25,26]. Fasting plasma samples for
determination of omentin-1 levels were collected before random-
ization and in the case of participants with DM2 after 24 weeks of
pioglitazone or metformin therapy.
Generation of Conditioned Media
CM was generated as described previously [3,27,28]. Briefly,
freshly collected adipose tissue biopsies were washed 3 times with
phosphate-buffered saline (PBS), supplemented with antibiotic-
antimycotic (Invitrogen, Carlsbad, CA, USA) at 37uC, and cut
into 10 mg pieces. Subsequently, the pieces were washed 3 times
with PBS, centrifuged for 1 min at 1200 rpm at room tempera-
ture, and cultured overnight in adipocyte medium containing
Dulbecco’s modified Eagle medium F12 supplemented with 10%
fetal calf serum, 33 mmol/L biotin, 17 mmol/L panthothenate (all
from Invitrogen, Carlsbad, CA, USA), and antibiotic-antimycotic,
in a humidified atmosphere (95% air and 5% CO2) at 37uC. Then,
CM was generated by culturing the explants in serum-free
adipocyte medium (100 mg explants/mL) for 24 h. The CM
was collected and stored as aliquots at 280uC until further use.
Omentin-1 Levels
Omentin-1 levels in human plasma and CM were determined
using an omentin-1 Enzyme Linked Immuno Sorbent Assay
(ELISA; USCN Life Science Inc, Cologne, Germany). The intra-
and interassay coefficients of variation for the omentin-1 ELISA
were less than 6.7% and 9.1%, respectively. For protein
expression, biopsies were homogenized in 50 mM Tris.HCl
[pH 7.5], 150 mM NaCl, 0.5% Triton X-100, 1 mM NaF,
1 mM Na3VO4, 2 mM MgCl2, 1 mM DTT, and protease
inhibitors (Complete, Roche Diagnostics, Mannheim, Germany).
Then, homogenates were cleared by centrifugation (15 min;
12.000 rpm; 4uC), and protein content was determined using
Bradford reagent (Biorad Laboratories, Munich, Germany).
Protein expression was determined by Western blot analysis of
ten microgram of protein using omentin-1 antibody (R&D
systems, Minnesota, MN, USA). Immunoblots were quantified
using a LUMI Imager system (Roche Diagnostics, Mannheim,
Germany), and normalized by reprobing the stripped filters with
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody
(Abcam plc, Cambridge, UK).
Preparation of Adult Rat Cardiomyocytes
Animal experiments were performed in accordance with the
‘Principle of laboratory animal care’ (NIH publication No. 85–23,
revised 1996) and the current version of the German Law on the
Omentin-1 and Cardiac Function
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protection of animals, and were approved by the animal ethics
committee of the Heinrich Heine University (Duesseldorf,
Germany). Cardiomyocytes were isolated from male Lewis rats
(Lew/Crl) weighing 150–300 gram using a Langendorff perfusion
system as described [29]. Briefly, rats were killed following
anaesthesia with ketamine (100 mg/kg; Ratiopharm, Ulm,
Germany) and xylazine (Rompun, 5 mg/kg) (Bayer Healthcare,
Leverkusen, Germany). The isolated heart was retrograde
perfused using a Langendorff perfusion system and digested with
a buffer containing collagenase (Worthington, Lakewood, NJ,
USA) and hyaluronidase (Applichem, Darmstadt, Germany).
Isolated cardiomyocytes were seeded in Medium 199 with Hank’s
salts, supplemented with ITS (insulin, transferrin, selenium),
100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal
calf serum (all from PAA laboratories, Pasching, Austria) on
laminin-coated 35 mm culture dishes (for signaling experiments:
Greiner Bio-One GmbH, Solingen, Germany; for fluorescence
analysis: ibidi GmbH, Martinsried, Germany). The medium was
renewed after 4 h, and culture was continued overnight.
Analysis of Contractile Function and Insulin Signaling
To determine contractile function, isolated cardiomyocytes were
cultured overnight and then preloaded with Fura-2-AM (Merck
chemicals, Darmstadt, Germany) for 25 min at room temperature.
Then, cultures were washed twice with adipocyte medium and
incubated for 30 min with CM (diluted 1:6 with adipocyte
medium) or adipocyte medium in the presence or absence of
300 ng/mL recombinant human omentin (Cell systems GmbH,
Germany; CS-C1212). Subsequently, sarcomere shortening and
Ca2+-transients were analyzed using an IonOptix system (Milton,
MA, USA) as described [3]. For analysis of Akt-phosphorylation
by Western blotting, cardiomyocytes were incubated for 24 h with
CM (diluted 1:6 with adipocyte medium) or adipocyte medium in
the presence or absence of 300 ng/mL recombinant human
Table 1. Characteristics of patients from which adipose tissue
biopsies were collected.
ND-patients
(n =11)
DM2-patients
(n=14)
Anthropometric parameters:
Age (years) 68.462.2 71.962.4
BMI (kg/m2) 26.961.3 28.961.1
Fasting plasma glucose (mg/dl) 96.8611 132620*
Medication use:
lipid-lowering 7 8
diuretics 4 6
anti-hypertension 9 8
glucose-lowering 0 5*
Data are presented as mean 6 SD. P-values for differences between
anthropometric variables were calculated using the Mann-Whitney U-test in
case of continuous data, and using Fisher’s exact test for medication use.
*P,0.05. BMI, body mass index; DM2, type 2 diabetes; ND, non-DM2.
doi:10.1371/journal.pone.0059697.t001
Figure 1. Expression and secretion of omentin-1 in intrathoracal adipose tissue depots. Representative Western blot (A) and
quantification (B) of omentin-1 expression in paired epicardial (EAT), pericardial (PAT), and subcutaneous (SAT) adipose tissue biopsies of patients
with (DM2, n = 7) and without (ND, n = 6) type 2 diabetes. Equal loading was verified by probing the immunoblots with glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody. (C) Quantification of omentin-1 levels in conditioned media generated from paired EAT, PAT and SAT explants
from DM2- and ND-patients. Data are expressed as mean 6 SEM (n= 6 patients per group). ***indicates P,0.001; **P,0.01, *P,0.05 for differences
between ND and DM2 (ANOVA followed by Bonferonni analysis for multiple comparisons); ###indicates P,0.001; ##P,0.01, and #P,0.05 for
differences between the various fat depots (paired t-test).
doi:10.1371/journal.pone.0059697.g001
Omentin-1 and Cardiac Function
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Table 2. Characteristics of subjects for determination of circulating omentin-1 levels.
Controls (n =14) DM2-patients (n =78)
Baseline characteristics, fat volume, insulin sensitivity
Age, years{ 54.567.1 56.565.6
BMI, kg/m2{ 27.062.5 28.763.5**
Disease duration, years{ n.a. 4 (2–6)
Visceral abdominal fat volume, mL 326 (195–422) 408 (300–531)*
Subcutaneous abdominal fat volume, mL 528630 6846258*
Pericardial fat volume, mL 26.9610.2 29.869.7
M-value, mg/kg.min{ 8.1 (7.4–10.0) 2.7 (1.6–4.2)***
Plasma parameters
Fasting plasma glucose, mmol/L{ 5.3 (5.0–5.6) 8.3 (7.1–10.0)***
Fasting plasma insulin, pmol/L{ 28 (19–33) 64 (36–92)***
HbA1c, %{ 5.360.2 7.161.0***
Total cholesterol, mmol/L{ 5.360.7 4.761.0***
HDL-cholesterol, mmol/L{ 1.4 (1.3–1.6) 1.1 (0.9–1.3)***
Triglycerides, mmol/L{ 0.9 (0.7–1.1) 1.5 (1.0–2.2)***
Plasma non-esterified fatty acids, mmol/L{ 0.46 (0.37–0.52) 0.50 (0.40–0.62)
Myocardial metabolism
Myocardial triglyceride content, %{ 0.57 (0.43–0.85) 0.81 (0.52–1.05)#
MMRglu, nmol/ml/min{ 834.96202.8 402.06152.6***
MFAU, nmol/ml/min{ 55.3 (45.0–71.6) 85.7 (63.7–130.8)*
MFAO, nmol/ml/min{ 51.9 (39.4–69.9) 77,6 (61.9–103.3)**
MFAE, nmol/ml/min{ 3.42 (1.70–5.59) 0.0011 (0–2.61)#
Hemodynamic parameters, cardiac dimensions and function
Systolic blood pressure, mm Hg{ 118611 128612***
Diastolic blood pressure, mm Hg{ 7268 7667*
Heart rate, beats/min{ 56 (51–62) 64 (60–70)***
Rate pressure product, (beats/min).mm Hg{ 668461441 834561457***
LV mass, gram{ 111624 107617
LV mass/volume ratio, gram/mL 0.6260.09 0.7060.11*
LV end diastolic volume, mL{ 181656 156625***
LV end systolic volume, mL{ 72 (63–82) 59 (52–71)**
Stroke volume, mL{ 107623 94616**
Ejection fraction, %{ 5964 6066
Cardiac output, L/min 623761324 617561160
Pulse wave velocity, m/s 5.4 (4.9–6.2) 6.3 (5.5–7.0)**
Aorta ascendens distensibility, 1023 mm Hg21 6.2 (4.8–7.7) 3.2 (2.3–5.9)***
E acceleration peak, mL/s2.1023 5.9 (4.9–8.7) 6.3 (5.6–7.5)
E acceleration mean, mL/s2.1023 4.3 (3.0–5.5) 4.0 (3.3–4.6)
E peak filling rate, mL/s{ 5036112 417684***
E deceleration peak, mL/s2.1023{ 4.73 (3.11–5.19) 3.40 (2.89–3.99)**
E deceleration mean, ml/s2.1023 2.7160.80 2.2660.67*
E/A peak ratio 1.2660.36 1.0460.25*
Data are mean 6 SD or median (interquartile range). P-values for differences between variables were calculated using the students t-test in case of normally distributed
data, or the Mann-Whitney U-test in case of non-Gaussian distributions data.
***indicates P,0.001;
**P,0.01;
*P,0.05;
#P,0.10. A, diastolic atrial contraction; BMI, body mass index; DM2, type 2 diabetes; E, early diastolic filling phase; HbA1c, glycated hemoglobin; HDL, high-density
lipoprotein; LV, left ventricular; MFAE, myocardial fatty acid esterification; MFAO, myocardial fatty acid oxidation; MFAU, myocardial fattu acid uptake; MMRGlu,
myocardial metabolic glucose metabolism; M-value, whole body insulin sensitivity.
{adapted from Rijzewijk et al. 2009 [23].
doi:10.1371/journal.pone.0059697.t002
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omentin. Then, cells were stimulated for 10 min with 100 nM
insulin, and lysed as described [3].
Statistical Analysis
Data are presented as mean 6 standard error of the mean or
median (interquartile range) in case of a non-Gaussian distribu-
tion. Significant differences between the variables were evaluated
as indicated in the legends to the Figures and Tables. Correlation
coefficients were calculated using the Pearson’s correlation.
Linearity of the regression models was judged based on histograms
and scatter plots. Because no interactions were found between
group and dependent variables, both groups were analyzed as one
for regression analysis. Additional potential confounders were
investigated by adding group state, BMI, and M-value for insulin
sensitivity for associations of omentin-1. Variables that changed
the regression coefficients by more than 10% were included in the
adjusted model. IBM SPSS Statistics version 20 was used for these
Figure 2. Plasma omentin-1 levels in men with uncomplicated type 2 diabetes. Plasma omentin-1 levels, fat distribution, insulin sensitivity
and diastolic parameters were determined in healthy control men (n = 14) and men with uncomplicated type 2 diabetes (DM2) (n = 78). (A) Whisker
plot (median, min-max) depicting plasma omentin-1 levels in controls and DM2-patients. Differences in circulating omentin-1 levels were analyzed
using a Mann-Whitney U-test. **indicates P,0.01. Regression analysis identified significant correlations between baseline omentin-1 plasma levels
and E peak filling rate (B), early deceleration peak (C), M-value (D), visceral fat volume (E), and systolic blood pressure (F). A straight line indicates
a regression line for all subjects. A dashed line indicates a regression line for healthy controls only.
doi:10.1371/journal.pone.0059697.g002
Omentin-1 and Cardiac Function
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Table 3. Correlations between plasma omentin-1 levels and anthropometric, plasma, hemodynamic parameters, and cardiac
dimensions and function.
All subjects (n =92) Controls (n =14) DM2-patients (n =78)
Baseline characteristics, fat volume, insulin sensitivity
Age, years 20.025 20.061 0.005
BMI, kg/m2 20.219* 20.069 20.184
Disease duration, years n.a. n.a. 0.131
Visceral abdominal fat volume, mL 20.269** 20.363 20.205#
Subcutaneous abdominal fat volume, mL 20.176# 0.037 20.149
Pericardial fat volume, mL 20.180# 20.288 20.138
M-value, mg/kg.min 0.379*** 0.502 0.322**
Plasma parameters
Fasting plasma glucose, mmol/L 20.227* 0.059 20.090
Fasting plasma insulin, pmol/L 20.378*** 0.117 20.379***
HbA1c, % 20.259* 20.589# 20.146
Total cholesterol, mmol/L 0.235* 0.703* 0.152
HDL-cholesterol, mmol/L 0.280** 0.187 0.230*
Triglycerides, mmol/L 20.173 0.474 20.131
Plasma non-esterified fatty acids, mmol/L 20.050 20.345 0.015
Myocardial metabolism
Myocardial triglyceride content, %{ 0.156 20.439 20.087
MMRglu, nmol/ml/min 0.142 20.106 0.142
MFAU, nmol/ml/min 20.115 20.510 20.057
MFAO, nmol/ml/min 20.130 20.420 20.064
MFAE, nmol/ml/min 20.008 20.128 20.030
Hemodynamic parameters, cardiac dimensions and function
Systolic blood pressure, mm Hg{ 20.130 0.709** 20.108
Diastolic blood pressure, mm Hg{ 20.037 0.476 20.113
Heart rate, beats/min{ 20.221* 20.210 20.153
Rate pressure product, (beats/min).mm Hg{ 20.243* 0.117 20.184
LV mass, gram{ 20.071 0.164 20.147
LV mass/volume ratio, gram/mL 20.167 0.181 20.144
LV end diastolic volume, mL{ 0.076 0.007 20.009
LV end systolic volume, mL{ 0.098 20.053 0.019
Stroke volume, mL{ 0.039 0.104 20.024
Ejection fraction, %{ 20.074 0.179 20.032
Cardiac output, L/min 20.098 0.020 20.125
Pulse wave velocity, m/s 0.031 0.067 0.060
Aorta ascendens distensibility, 1023 mm Hg21 0.175# 0.006 0.132
E acceleration peak, mL/s2.1023 0.148 0.316 0.122
E acceleration mean, mL/s2.1023 0.146 0.207 0.114
E peak filling rate, mL/s{ 0.246* 0.325 0.182
E deceleration peak, mL/s2.1023{ 0.221* 0.232 0.185
E deceleration mean, mL/s2.1023 0.218* 0.278 0.179
E/A peak ratio 0.139 0.419 0.040
Data are Pearson’s r. In case of non-Gaussian distributions, parameters were ln-transformed for correlation analysis. A, diastolic atrial contraction; BMI, body mass index;
DM2, type 2 diabetes; E, early diastolic filling phase; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LV, left ventricular; MFAE, myocardial fatty acid
esterification; MFAO, myocardial fatty acid oxidation; MFAU, myocardial fattu acid uptake; MMRGlu, myocardial metabolic glucose metabolism; M-value, whole body
insulin sensitivity.
#P,0.10;
*P,0.05;
**P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0059697.t003
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analyses. A value of P,0.05 was considered as statistically
significant.
Results
Expression and Secretion of Omentin-1 in Adipose Tissue
Depots
Omentin-1 expression was determined in adipose tissue biopsies
collected from patients with and without DM2 undergoing open
heart surgery. As shown in Table 1, both groups had comparable
age and BMI, while fasting blood glucose levels were elevated in
patients with DM2. Omentin-1 protein expression was highest in
EAT from non-DM2 subjects as compared to pericardial and
subcutaneous adipose tissue from the same patient, respectively
(Figure 1A/B). Furthermore, omentin-1 levels in EAT were
reduced in patients with DM2 versus non-DM2 patients (P,0.01)
(Figure 1A/B). Analysis of CM showed highest omentin-1
secretion by EAT and pericardial adipose tissue as compared to
subcutaneous adipose tissue in non-DM2 patients (Figure 1C).
Furthermore, omentin-1 levels in CM were markedly reduced in
DM2 (Figure 1C).
Circulating Omentin-1 Levels in Type 2 Diabetes and
Controls
Plasma omentin-1 levels were determined in 78 men with
uncomplicated DM2 and 14 healthy controls. Detailed baseline
and cardiometabolic parameters of the participants have been
described previously [23]. Briefly, patients with DM2 had a slightly
higher BMI, increased systolic and diastolic blood pressure,
visceral fat and subcutaneous fat volumes, as well as elevated
HbA1c and fasting plasma glucose and insulin levels (all P,0.05)
(Table 2). Furthermore, patients with DM2 versus healthy controls
had a lower M-value for insulin sensitivity, impaired left
ventricular diastolic function, increased pulse wave velocity, and
decreased distensibility of the aorta ascendens (all P,0.05)
(Table 2). As compared to controls, median plasma omentin-1
levels were lower in patients with DM2 (313 versus 426 ng/mL;
P=0.008) (Figure 2A).
Univariate regression analysis identified inverse correlations
between plasma omentin-1 levels and BMI, fasting plasma glucose,
insulin and HbA1c, visceral fat volume, heart rate, and rate
pressure product, and positive associations with the diastolic
parameters early peak filling rate, early deceleration peak and
early deceleration mean, M-value for insulin sensitivity, adipo-
nectin and HDL-cholesterol (Table 3, Figure 2B–F). Only in
controls, omentin-1 levels associated with systolic blood pressure
Figure 3. Plasma omentin-1 levels in men with uncomplicated type 2 diabetes before and after 24-week pioglitazone treatment
versus 24-week metformin treatment. (A) Plasma omentin levels before (0) and after 24 weeks of treating males with uncomplicated type 2
diabetes with metformin or pioglitazone. P-values for treatment-effects were calculated using a Wilcoxon signed rank test. **indicates a P,0.01.
Pearson regression analysis showed that only in the pioglitazone group changes in omentin-1 levels positively correlated with changes in early peak
filling rate (B), early deceleration peak (C), and early deceleration mean (D).
doi:10.1371/journal.pone.0059697.g003
Omentin-1 and Cardiac Function
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(Table 3, Figure 2F). In multivariate regression analysis, the
associations between omentin-1 plasma levels and early peak filling
rate and early deceleration mean were independent of diabetic
state, BMI, and M-value (respectively b=0.247; P=0.04;
b=0.255, P=0.004). The association between omentin-1 plasma
levels and early deceleration peak was borderline significant in this
analysis (b=0.233; P= 0.06).
Treating patients with DM2 with pioglitazone or metformin led
to similar improvement of glycemic control, but only pioglitazone
treatment resulted in improved left ventricular diastolic function
Figure 4. Effect of recombinant omentin on sarcomere shortening and calcium fluxes in primary adult rat cardiomyocytes. Primary
rat cardiomyocytes were incubated with control medium or conditioned media from epicardial adipose tissue from patients with type 2 diabetes
(EAT) for 30 min in the absence or presence of recombinant omentin before analysis of sarcomere shortening and cytosolic Ca2+-fluxes. Effect of
exposure of cardiomyocytes to EAT and omentin on departure velocity of contraction (A), peak sarcomere shortening (B), return velocity of
contraction (C), departure velocity of cytosolic [Ca2+] (D), peak fura-2 fluorescence (E) and departure velocity of cytosolic [Ca2+] (F). Data were
collected during at least 4 independent experiments using cardiomyocyte preparations from different rats and conditioned media from different
donors, and are expressed as mean 6 standard error of the mean. Differences among the groups were evaluated using the Kruskal-Wallis method
followed by a Dunns multiple comparison test. ***P,0.001; **P,0.01, versus control adipocyte medium (control), ###P,0.001; ##P,0.01 EAT
versus EAT+omentin.
doi:10.1371/journal.pone.0059697.g004
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[22]. Plasma omentin-1 levels were increased in patients with
DM2 following pioglitazone (baseline versus pioglitazone: 257
versus 375 ng/mL; P=0.002), but not metformin, treatment
(Figure 3A). Furthermore, changes in omentin-1 levels were
correlated with changes in early peak filling rate, early de-
celeration peak and early deceleration mean in patients with DM2
after 24-week of pioglitazone treatment, but not after metformin
treatment (Figure 3B–D).
Effect of Recombinant Omentin on Cardiomyocyte
Contractile Function and Insulin Action
The above findings suggest that increases in omentin-1 levels
could beneficially affect cardiac function in patients with DM2. To
substantiate this, we investigated whether recombinant omentin
could prevent the induction of cardiomyocyte dysfunction by CM
generated from EAT from patients with DM2 (CM-EAT).
Exposure of primary rat cardiomyocytes to CM-EAT reduced
peak sarcomere shortening and the departure and return velocity
of contraction as compared to cardiomyocytes exposed to control
medium (Figure 4A–C). Omentin alone had no effect on
contractile function, but partially prevented the reductions in the
parameters of sarcomere shortening induced by CM-EAT
(Figure 4A–C). Furthermore, the abrogation in cytosolic Ca2+-
transients induced by CM-EAT, as illustrated by reductions in
departure and return velocities and a lower peak Fura-2
fluorescence signal, was fully reversed by the presence of omentin
(Figure 4D–F). Finally, we examined the effect of omentin on the
reduction of insulin-stimulated Akt-phosphorylation caused by
exposure of cardiomyocytes to CM-EAT. As shown in Figure 5,
omentin alone had no significant effect on insulin-mediated Akt-
phosphorylation. Yet, the presence of omentin prevented the
abrogation of insulin-mediated Akt-phosphorylation induced by
CM from patients with DM2 (Figure 5).
Discussion
Here we show that decreases in circulating omentin-1 levels
associate with left ventricular diastolic dysfunction. In patients with
DM2, circulating omentin-1 levels were lower as compared to
controls. Pioglitazone treatment, which improved left ventricular
diastolic function in this study cohort [22] increased plasma
omentin-1 levels. Furthermore, in pioglitazone-treated patients
with DM2, the increments in plasma omentin-1 levels correlated
positively with the observed changes in diastolic function. Finally,
in cardiomyocytes, the presence of omentin prevented the
induction of contractile dysfunction and insulin resistance by
CM-EAT from patients with DM2. Collectively, these findings
provide evidence for a cardioprotective function of omentin-1, and
suggest that decreases in omentin levels may contribute to the
pathogenesis of cardiac dysfunction in DM2.
This study confirmed that circulating omentin-1 levels are lower
in patients with DM2 versus controls [10,12], that positive
associations exist between omentin-1 levels and insulin sensitivity,
adiponectin, and high-density lipoprotein cholesterol, and that
negative associations exist between omentin-1 levels and measures
of adiposity, such as BMI, visceral fat volume, fasting plasma
insulin and glucose levels [8,10,11,13,14]. Circulating omentin-1
levels also weakly associate with endothelial function in men with
normal and impaired glucose tolerance [9,14]. We observed
a weak tendency of omentin-1 levels associating with aorta
distensibility, but not with pulse wave velocity. Other studies
reported increases in omentin-1 levels following a 6–month
metformin intervention in women with the polycystic ovary
syndrome [30], and following treatment of Chinese patients with
DM2 with poor glycemic control with metformin combined with
liraglutide [31]. Although metformin improved glycemic control
[22], we observed no effect of metformin on omentin-1 levels in
our study population containing men with well-controlled DM2. It
remains to be clarified whether this can be ascribed to differences
among the study cohorts, such as gender, glycemic control, disease
status, ethnicity, and the lack of a ‘metformin only’ group in the
Chinese study [31].
A major finding in our study is the association of plasma
omentin-1 levels with left ventricular diastolic function. Because of
the strong positive association with adiponectin levels, omentin-1
levels may be regulated by adiponectin [12]. Like omentin-1,
adiponectin positively associates with insulin sensitivity and high-
density lipoprotein cholesterol, and negatively with BMI, and waist
circumference, but not with parameters of left ventricular diastolic
function in this study population [32]. Although these findings do
not exclude a role for adiponectin in the regulation of omentin-1,
the data suggest a direct cardioprotective effect of omentin-1
rather than adiponectin-mediated.
In vitro studies have indeed ascribed a signaling function to
omentin-1 because it promotes Akt-phosphorylation in isolated
blood vessels, vascular smooth muscle cells, and microvascular
endothelial cells [30,33,34], and enhances insulin-mediated Akt-
Figure 5. Effect of recombinant omentin on insulin action in
primary adult rat cardiomyocytes. Western blot (A) and quantifi-
cation (B) of recombinant omentin on insulin action. Lysates from
primary adult rat cardiomyocytes exposed for 24 h to control adipocyte
medium (control) or recombinant omentin in the absence or presence
of conditioned media generated from epicardial adipose tissue from
patients with type 2 diabetes (EAT) were analyzed for insulin-induced
Akt-Ser473-phosphorylation. Data were collected during at least 6
independent experiments using cardiomyocyte preparations from
different rats and conditioned media from different donors, and are
expressed as mean 6 standard error of the mean. Open bars, basal;
filled bars, insulin stimulated cells. Differences among the groups were
evaluated by ANOVA following Bonferroni analysis for multiple
comparisons. *P,0.001 effect of insulin (filled bars) versus basal (open
bars); ###P,0.001 control versus EAT, ##P,0.01 EAT versus EAT+o-
mentin.
doi:10.1371/journal.pone.0059697.g005
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phosphorylation and glucose uptake in adipocytes [15]. Further-
more, omentin-1 has an anti-inflammatory action as illustrated by
its ability to reduce the induction of migration, angiogenesis, and
activation of nuclear factor kappa B (NF-kB) and p38 by pro-
inflammatory factors in endothelial cells and smooth muscle cells
[16,30]. In recent studies, we observed that factors secreted from
EAT can directly affect contractile function and insulin action in
primary adult rat cardiomyocytes [3,6]. Moreover, we could show
that DM2 induces qualitative alterations in the secretory profile of
EAT, which may contribute to the induction of cardiac
dysfunction [6]. In the present study, we demonstrated that
circulating omentin-1 levels and omentin-1 released from EAT are
reduced in DM2. Analysis of omentin-1 action in cardiomyocytes
showed that omentin alone had no effect on sarcomere shortening,
cytosolic Ca2+-fluxes and Akt-phosphorylation in cardiomyocytes.
Rather, omentin-1 was found to protect against the induction of
cardiomyocyte contractile dysfunction and insulin resistance by
EAT-released factors from patients with DM2. This suggests that
omentin-1 could exert its cardioprotective effects by acting as
a scavenger for detrimental factors secreted by adipose tissue.
Yet, several issues remain to be addressed. First of all, this study
was conducted in men, and it is unclear to what extent our findings
can be applied to women. In this respect, the clinical studies that
addressed this issue reported no impact of gender on circulating
omentin-1 levels [35–38]. However, one should note that others
reported conflicting data with elevated levels found in both men
and women as compared to the other gender [8,12], and
sometimes dependent on disease status [31]. Furthermore, it is
unclear how omentin-1 synthesis is regulated in response to
external stimuli. In adipose tissue, omentin-1 is predominantly
produced by the stromal vascular fraction [15], which contains
a wide variety of non-adipose cells, including pre-adipocytes,
endothelial cells, stem cells, fibroblasts, and immune cells. Adipose
tissue in DM2 is characterized by infiltration of immune cells and
an enhanced secretion of pro-inflammatory adipokines [39]. These
factors may result in the induction of apoptosis and endoplasmic
reticulum stress and consequently inhibition of the synthesis of
abundantly expressed proteins. Finally, the beneficial effects of
pioglitazone on circulating omentin-1 levels in patients with DM2
may also implicate a critical role for peroxisome proliferator
activated receptor-c in the regulation of omentin-1 production.
However, because of the complex cellular composition of adipose
tissue, it may be preferable to specify the cell type(s) in which
omentin-1 is produced first, before studying a contribution of
regulators of omentin-1 synthesis.
Conclusions
This study shows that omentin-1 levels in plasma and EAT are
decreased in patients with DM2. Furthermore, the positive
association of omentin-1 levels with left ventricular diastolic
function and the experiments in isolated rat cardiomyocytes
suggest that omentin-1 could have a cardioprotective function.
Accordingly, a reduction in omentin-1 expression in EAT might
contribute to the induction of cardiac dysfunction in patients with
DM2.
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